Drug intelligence / Profile preview

TJAOA102 (Tongji Hospital)

Development stage: Unknown
Lead developer: Tongji Hospital
Modality: Small Molecules
Administration: Oral

Overview

TJAOA102 is a Chinese herbal compound developed by Tongji Hospital for the treatment of menopausal syndrome, premature ovarian insufficiency (POI), and diminished ovarian reserve (DOR). As a Traditional Chinese Medicine (TCM) formulation, it is designed to alleviate menopausal symptoms and support ovarian function. The compound has been validated in animal models and is currently undergoing multicenter, prospective clinical trials to establish its safety and efficacy in human populations as a potential alternative or adjunct to conventional hormone replacement therapy.

Brand names: TJAOA 102TJAOA102TJAOA-102
Other names: Chinese herbal compound TJAOA102

Beyond the preview

Go deeper on TJAOA102 (Tongji Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJAOA102 (Tongji Hospital).

Explore the full profile